A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Status:
Recruiting
Trial end date:
2025-07-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing
clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure
(pharmacokinetics [PK]) in pediatric participants with moderately to severely active UC.